P105 - Patient Reported Burden of Disease in Diabetic Peripheral Neuropathic Pain: Learnings from In-depth Patient Interviews, Sub-Study of RELIEF-DPN 1

Diabetic peripheral neuropathy (DPN) often results in diabetic peripheral neuropathic pain (DPNP) which is difficult to manage effectively with the current standards of care. This poster describes RELIEF-DPN 1, a Phase-2 study in adult patients with Type 1 or 2 diabetes and moderate to severe established DPNP, evaluated the safety and efficacy of LX9211, a potent non-opioid inhibitor of AP2-associated protein kinase 1 (AAKI). A sub-study of RELIEF-DPN 1, employed patient interviews with the objectives of characterizing pre-trial patient-reported disease burden and assessing unmet needs in DPNP management. The results will provide thematic qualitative data that describes symptoms and aspects of daily living impacted by DPNP that are burdensome from a patient's perspective and will highlight the need for improved therapy and innovation in DPNP management.